Penny-wise, pound-foolish? Highmark Medicare Services' proposal for anticoagulation clinic reimbursement

Annals of Pharmacotherapy

Volumn 44, Issue 4, 2010, Pages 733-736

  Streiff, Michael B ^a,b   Kraus, Peggy S ^b   Pronovost, Peter ^c,d  

^a Johns Hopkins Anticoagulation Management Service   (Canada)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Anticoagulation; Anticoagulation clinic; Center for Medicare; Health care economics; Medicaid Services; Warfarin

Indexed keywords

WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH MAINTENANCE ORGANIZATION; HEALTH SERVICE; HUMAN; MEDICAID; MEDICARE; NOTE; PATIENT SAFETY; PRIORITY JOURNAL; REIMBURSEMENT; SELF EVALUATION; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HEART VALVE PROSTHESIS; HUMANS; MEDICAID; MEDICARE; OUTPATIENT CLINICS, HOSPITAL; QUALITY OF HEALTH CARE; REIMBURSEMENT MECHANISMS; THROMBOEMBOLISM; UNITED STATES; WARFARIN;

EID: 77950606063     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M666     Document Type: Note

References (33)

1. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest 2008;133(6 suppl):546S-92S. DOI 10.1378/chest.08-0678
2. Salem DN, O'Gara PT, Madias C, Pauker SG. Valvular and structural heart disease: American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest 2008;133(6 suppl):593S-629S. DOI 10.1378/chest.08-0724 (Pubitemid 351892973)
3. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest 2008;133(6 suppl):454S-545S. DOI 10.1378/chest.08-0658 (Pubitemid 351892971)
4. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007;167:1414-1419 (Pubitemid 47052441)
5. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence- based clinical practice guidelines. 8th ed. Chest 2008;133(6 suppl):160S- 98S. DOI 10.1378/chest.08-0670 (Pubitemid 351892967)
6. Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007;147:755-765 (Pubitemid 351664440)
7. Torn M, Cannegieter SC, Bollen WL, et al. Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients. Arch Intern Med 2009; 169:1203-1209
8. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-1026 (Pubitemid 37087616)
9. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007;120:700-705 DOI 10.1016/j.amjmed.2006.07.034 (Pubitemid 47176507)
10. The Joint Commission Accreditation Program: Hospital - The National Patient Safety Goals. www.jointcommission.org/NR/rdonlyres/31666E86- E7F4- 423E-9BE8-F05BD1CB0AA8/0/HAP-NPSG.pdf (accessed 2009 Dec 24).
11. Cortelazzo S, Finazzi G, Viero P, et al. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost 1993;69:316-320 (Pubitemid 23103115)
12. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic and usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998;158:1641-1647 (Pubitemid 28371187)
13. Witt DM, Sadler MA, Shanahan RL, et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005;127:1515-1522 DOI 10.1378/chest.127.5.1515 (Pubitemid 46218774)
14. Baglin TP, Keeling DM, Watson HG; British Committee for Standards in Haematology. Guidelines on oral anticoagulation (warfarin): 3rd ed.- 2005 update. Br J Haematol 2006;132:277-285 DOI: 10.1111/j.1365-2141.2005.05856.x
15. Palareti G. A guide to oral anticoagulant therapy. Italian Federation of Anticoagulation Clinics. Haemostasis 1998;28(suppl 1):1-46. DOI:10.1159/ 000054103 (Pubitemid 28541137)
16. Garcia DA, Witt DM, Hylek E, et al. Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother 2008;42:979-988 DOI 10.1345/aph.1L098
17. Highmark Medicare Services position on the necessity of E/M services submitted as a component service of anticoagulation management, July 27, 2009. www.highmarkmedicareservices.com/bulletins/all/news-07272009. html (accessed 2009 Dec 13).
18. A/B MAC Jurisdiction 1. Medicare fee-for-service claims processor. www.cms.hhs.gov/MedicareContractingReform/Downloads/ PrimaryABMACJurisdictionFactSheets.pdf (accessed 2009 Dec 13).
19. Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis 1998;5(suppl):19-24. (Pubitemid 128689811)
20. Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis 2000;9:283-292 DOI 10.1023/A:1018778914477
21. Shalev V, Rogowski O, Shimron O, et al. The interval between pro- thrombin time tests and the quality of oral anticoagulant treatment in patients with chronic atrial fibrillation. Thromb Res 2007;120:201-206 DOI 10.1016/j.thromres.2006.10.001 (Pubitemid 46754418)
22. Rose AJ, Ozonoff A, Berlowitz DR, et al. Warfarin dose management affects INR control. J Thromb Haemost 2009;7:94-101. DOI 10.1111/j.1538-7836.2008. 03199.x
23. Wittkowsky AK, Nutescu EA, Blackburn J, et al. Outcomes of oral anticoagulant therapy managed by telephone vs in- office visits in an anticoagulation clinic setting. Chest 2006;130:1385-1389 (Pubitemid 44786730)
24. Press release. Medicare announces expanded coverage for warfarin patients monitoring clotting time at home. www.medicalnewstoday.com/ar- ticles/101149.php (accessed 2009 Dec 13).
25. Connock M, Stevens C, Fry-Smith A, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess 2007;11:iii-iv, ix-66. (Pubitemid 351359078)
26. Medicare HMO withdrawals and pullouts. www.insbuyer.com/hmowithdrawals. htm (accessed 2009 Dec 13).
27. Center for Medicare and Medicaid Services. Overview mission, goals and vision. www.cms.hhs.gov/MissionVisionGoals/ (accessed 2009 Dec 13).
28. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2009;119:480-486 DOI 10.1161/CIRCULATIONAHA.108.191259
29. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009;150:73-83.
30. Sullivan PW, Arant TW, Ellis SL, Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics 2006;24:1021-1033 (Pubitemid 44497473)
31. You JH, Chan FW, Wong RS, Cheng G. Cost-effectiveness of two models of management for patients on chronic warfarin therapy - a Markov model analysis. Thromb Haemost 2003;90:1106-1111 DOI 10.1160/TH03-06-0367 (Pubitemid 38004431)
32. Lafata JE, Martin SA, Kaatz S, Ward RE. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med 2000;15:31-37 DOI 10.1046/j.1525-1497.2000.01239.x (Pubitemid 30060936)
33. Witt DM, Delate T, Clark NP, et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood 2009; 114:952-956 DOI 10.1182/blood-2009-02-207928